Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 656-664

  Giles, Francis J ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge E ^a   Baker, Sharyn D ^a   Miller, Carol B ^a   O'Brien, Susan M ^a   Thomas, Deborah A ^a   Andreeff, Michael ^a   Bivins, Carol ^a   Jolivet, Jacques ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BUSULFAN; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; HOMOHARRINGTONINE; HYDROXYUREA; IDARUBICIN; IMATINIB; METHOTREXATE; MITOXANTRONE; NUCLEOSIDE ANALOG; TALLIMUSTINE; THYMOCYTE ANTIBODY; TIOGUANINE; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLAST CELL CRISIS; BONE MARROW HYPOPLASIA; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKEMIA; LYMPHATIC LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION;

EID: 0036467689     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.656     Document Type: Article

References (43)

1. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
2. Fludarabine: Present status and future developments in chronic lymphocytic leukemia and lymphoma
3. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions
4. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
5. Anti-human immunodeficiency virus and anti- hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro
6. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC and its arylphosphoramidate derivative CF 1109)
7. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus
8. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
9. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration
10. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU- 145 cells
11. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models
12. Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units
13. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
14. L- and D-Enandomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases: Implications for the mechanism of toxicity
15. A novel action of human apurinic/apyrimidinic endonuclease: Excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA
16. Excision of beta-D- and beta-L-nucleotide analogs from DNA by the human cytosolic 3′- to-5′ exonuclease
17. Excision of beta-L-and beta-D-nucleotide analogs from DNA by p 53 protein
18. Removal of anti-human immunodeficiency virus 2′,3′-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3′→5′ exonuclease
19. The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine
20. Exonucleases and the incorporation of aranucleotides into DNA
21. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′→5′ exonucleases
22. Identification of a 3′→5′-exonuclease that removes cytosine arabinoside monophosphate from 3′ termini of DNA
23. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo
24. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy
25. Transfer of the cytidine deaminase cDNA into hematopoietic cells
26. Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC)
27. Ara-C: Cellular and molecular pharmacology
28. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial
29. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia
30. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia
31. Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy
32. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
33. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
34. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
35. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase
36. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study
37. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
38. Topotecan in the treatment of hematologic malignancies
39. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia
40. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
41. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
42. Activity of an abl specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
43. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome